ACCELERATE. 5 th ACCELERATE Paediatric Oncology Conference SIOP. Brussels, Belgium 2 3 March 2017 CDDF ADVANCE PROGRAMME
|
|
|
- Ross Porter
- 5 years ago
- Views:
Transcription
1 ACCELERATE INNOVATION FOR CHILDREN AND ADOLESCENTS WITH CANCER ACCELERATE PLATFORM (CDDF-ITCC-SIOPE MULTI-STAKEHOLDER PLATFORM) 5 th ACCELERATE Paediatric Oncology Conference Brussels, Belgium 2 3 March 2017 CDDF Cancer Drug Development Forum SIOP SIOP Europe the European Society for Paediatric Oncology
2 Day 1 Thursday 2 nd March :30 Introduction Gilles Vassal (ACCELERATE platform) SESSION 1 : LEARNING FROM SUCCESS AND FAILURE IN PEDIATRIC ONCOLOGY DRUG DEVELOPMENT Chairs: Anne Goeres (Unite2cure, LU) & Ralf Herold (European Medecines Agency, UK) 13:50 Successful practice changing development plans: Rituximab in Burkitt lymphoma Véronique Minard (Gustave Roussy, FR) 14:05 Unfeasible development plans : Vemurafenib in melanoma in adolescents Stephen Simko (Genentech/Roche, USA) 14:20 Feasibility of Mechanism of Action driven development plans: Dabrafenib in B-RAF mutated pediatric malignancies 14:35 Delays in implementing pediatric oncology developments: Inotuzumab in leukemias Peter Adamson (Children s Oncology Group / The Children s Hospital of Philadelphia, USA) 14:50 Round table and discussion : How to build on lessons learnt? Participants: Cesare Spadoni (apodd Foundation, UK) 16:00 Coffee break SESSION 2 : WHERE ARE WE AFTER 10 YEARS? Chair: Martin Schrappe (SIOPE, DE) 16:30 The 10 year EMA report on the EU regulation with a focus on oncology Dirk Mentzer (European Medicines Agency, UK) 16:45 The EU economic assessment study To be annouced 17:00 Impact of the US regulations (BPCA, PREA) on pediatric oncology development Martha Donoghue (FDA, US) 17:15 Raising awareness and the EU political agenda Delphine Heenen (Unite2cure, BE) 17:30 Raising awareness in the US Susan Weiner (CCCA - Children s Cause for Cancer Advocacy, USA) 17:45 Round table discussion : what are the changes needed? Participants: Pamela Kearns (Cancer Research UK / University of Birmingham, UK) 18:45 End of day 1 19:45 Networking dinner
3 Day 2 Friday 3 th March 2017 SESSION 3 : ONGOING INITIATIVES TO IMPROVE THE EFFICIENCY OF PEDIATRIC DRUG DEVELOPMENT Chairs: Chris Copland (Unite2cure, UK) & Dirk Mentzer (European Medicines Agency, UK) 08:30 Scrutinizing class waived oncology drugs: could it be done differently? Andy Pearson (ITCC, UK) 08:45 The IMI2 ITCC-P4 pediatric preclinical proof of concept platform Louis Stancato (Lilly, USA) 09:00 Getting rid of the 18-year dogma Nathalie Gaspar (Gustave Roussy, FR) 09:15 Pediatric Strategy Forum : a new concept proposed by ACCELERATE Andy Pearson (ITCC, UK) 09:30 Developing new medicines for children with neuromuscular diseases 09:45 Complementary questions to speakers 10:00 Coffee break Round table discussion: identify barriers and propose solutions Participants: Nicole Scobie (Childhood Cancer International, CH) 12:00 Lunch SESSION 4 : ACCELERATING Chairs: Nicole Scobie (Childhood Cancer International, CH) & Samuel Blackman (Silverback Therapeutics, USA) 13:00 Setting up the base line : Timing for approval of oncology PIPs Gilles Vassal (Gustave Roussy, FR) 13:15 The imatrix Raphael Rousseau (Genentech / Roche, USA) 13:30 The Pediatric MATCH trial Peter Adamson (Children s Oncology Group / The Children s Hospital of Philadelphia, USA) 13:45 The ITCC strategy Birgit Geoerger (Gustave Roussy, France) 14:00 Discussion: how to accelerate innovation for children and adolescents with cancer? Participants: Patricia Blanc (Unite2cure, Imagine for Margo, FR) 14:45 Coffee break
4 SESSION 5 : INVESTING IN PEDIATRIC ONCOLOGY DRUG DEVELOPMENT Chairs: Jeffrey Skolnik (Inovio Pharmaceuticals, USA) & Patricia Blanc (Unite2cure, Imagine for Margo, FR) 15:15 10 years of rewarding in the EU pediatric regulation 15:30 Proposals for change from Accelerate Pamela Kearns (Cancer Research UK / University of Birmingham, UK) 15:45 New perspectives in pediatric oncology drug development 16:00 Discussion: think out of the box - how to fund and invest in pediatric oncology drug development? Participants: Anne Goeres (Unite2cure, LU) & Delphine Heenen (Unite2cure, BE) 17:00 Conclusion - Defining next steps forward together Gilles Vassal (Gustave Roussy, FR) 17:45 End of the conference
5 Event Outline The conference is part of a unique multi-stakeholder joint initiative, the ACCELERATE multi-stakeholder Platform. Co-organised by CDDF, ITCC and SIOPE, this platform provides a transparent forum enabling patients and parents organisations, academic paediatric oncologists and haematologists, pharmaceutical companies and EU regulatory network representatives to collaborate and jointly address specific obstacles to a faster and more effective treatments for children and adolescents with cancer, including the needed changes to the Paediatric Medicines Regulation. Innovative therapies could target several paediatric malignancies and, thus, save many young lives. However today less than 1 in 10 children in relapse with a terminal cancer has access to these types of medicines, and investment in paediatric oncology drug development is insufficient. Paediatric drug development is currently regulated in Europe via the EU Paediatric Regulation (EC No 1901/2006) is the year of the 10th year report by the European Commission on this Regulation: 10 years of learning, 10 years of success and failure, 10 years of interaction between stakeholders; a huge experience to build upon in order to accelerate innovation for children and adolescents with cancer. The annual conference is a unique occasion for high-level experts to reflect upon and discuss concrete proposals to accelerate new oncology drug development for children and adolescents. Programme chairs Gilles Vassal (ACCELERATE platform chair, France) Patricia Blanc (Imagine for Margo, France & Unite2Cure) Silvia Chioato (Pfizer, Italy) Ralf Herold (European Medicines Agency, UK) Peter Lack (Childhood Cancer International, Switzerland & Unite2Cure) Koenraad Norga (Antwerp University Hospital, Belgium & vice-chair PDCO, EMA) Andrew Pearson (The Institute of Cancer Research, UK & ITCC) Raphael Rousseau (Roche Genentech, USA) Stefan Schwoch (Eli Lilly, UK) Nicole Scobie (Childhood Cancer International, Switzerland & Unite2Cure) Jeffrey Skolnik (Inovio Pharmaceuticals, USA) Heinz Zwierzina (Innsbruck University - CDDF, Austria) Who should attend the conference? Anyone interested in the developing field of new life-saving medicines for children and adolescents with cancer: patients and parents organizations, academic paediatric oncologists and haematologists, pharmaceutical companies and EU regulatory network representatives.
6 Why should you attend the Conference? To discuss successes and failures in paediatric development, and share new initiatives in clinical development To discuss the strategies to accelerate new oncology drug development To share and discuss the 10 years report of the Paediatric Regulation and changes in the regulatory environment To share experience and harmonize with the US, Canada, Japan, and Australia To further strengthen the collaboration between all stakeholders at the international level Venue Thon Hotel EU Rue de la Loi 75, B-1040 Brussels, Belgium Phone: +32 (0) Website: Conference Secretariat The Cancer Drug Development Forum (CDDF) office C/O ECCO Avenue E. Mounier Brussels, Belgium Phone: +32 (0) VISIT & REGISTER CDDF Cancer Drug Development Forum SIOP SIOP Europe the European Society for Paediatric Oncology
ACCELERATE. 6 TH ACCELERATE Paediatric Oncology Conference. Brussels, Belgium 8-9 February 2018 PROGRAMME ACCELERATE MULTISTAKEHOLDER PLATFORM
ACCELERATE INNOVATION FOR CHILDREN AND ADOLESCENTS WITH CANCER ACCELERATE MULTISTAKEHOLDER PLATFORM 6 TH ACCELERATE Paediatric Oncology Conference Brussels, Belgium 8-9 February 2018 PROGRAMME PROGRAMME
BDA IMPROVING ONCOLOGY DRUG DEVELOPMENT FOR CHILDREN AND ADOLESCENTS NOVEMBER 2013 WORKSHOP ADVANCE PROGRAMME
BDA WORKSHOP IMPROVING ONCOLOGY DRUG DEVELOPMENT FOR CHILDREN AND ADOLESCENTS 18-19 NOVEMBER 2013 PARIS, FRANCE BIOTHERAPY DEVELOPMENT ASSOCIATION encca European Network for Cancer Research in Children
Facilitate prioritisation: The ACCELERATE-EMA Paediatric Strategy Forums. Andy Pearson and Nicole Scobie
Facilitate prioritisation: The ACCELERATE-EMA Paediatric Strategy Forums Andy Pearson and Nicole Scobie 1 The ACCELERATE-EMA Paediatric Strategy Forums Organising Committee ACCELERATE Gilles Vassal, Andy
Development of Paediatric Medicines: From Learning to Adapting
Preliminary Programme Joint EFGCP / DIA / EMA Medicines for Children Conference on Development of Paediatric Medicines: From Learning to Adapting 26 & 27 September 2012 De Vere Venues Canary Wharf, London,
CURRENT AND FUTURE CHALLENGES OF INNOVATIVE ONCOLOGY DRUG DEVELOPMENT
CDDF Cancer Drug Development Forum CDDF 8 TH ALPINE CONFERENCE CURRENT AND FUTURE CHALLENGES OF INNOVATIVE ONCOLOGY DRUG DEVELOPMENT INNSBRUCK, AUSTRIA 2-4 MARCH 2015 Workshop objectives The goal of the
ITCC-P4 International Workshop
ITCC P4 GA No. 116064 ITCC-P4 International Workshop IMPROVING PEDIATRIC ONCOLOGY DRUG DEVELOPMENT THROUGH PRECLINICAL RESEARCH September 27 th and 28 th, 2018 // Amsterdam, NL By invitation The event
Preliminary Programme Version 9 September 2010 EFGCP Children s Medicines Working Party 6th Annual Conference & DIA Paediatric SIAC 4th Forum Current & Future Perspectives for Paediatric Medicines: Visions,
The EFGCP Children s Medicines Working Party 3 rd Annual Conference EU Paediatric Regulation: First European Experiences & Strategic Outlook
The EFGCP Children s Medicines Working Party 3 rd Annual Conference EU Paediatric Regulation: First European Experiences & Strategic Outlook 9 October 2007 - Management Centre Europe, Brussels, Belgium
Final Programme EFGCP Children s Medicines Working Party 6th Annual Conference & DIA Paediatric SIAC 4th Forum Current & Future Perspectives for Paediatric Medicines: Visions, Daily Challenges, Ways Forward
Paediatric Strategy Forum A new concept proposed by ACCELERATE
A new concept proposed by ACCELERATE 1 2 s Objective - provide a unique opportunity for interaction between all stakeholders (regulators, pharmaceutical companies, clinical and researcher academics and
The 10 year EMA report on the EU regulation with a focus on oncology
The 10 year EMA report on the EU regulation with a focus on oncology 5 th Annual Paediatric Oncology Conference Presented by Koenraad Norga & Franca Ligas on 2 March 2017 An agency of the European Union
Current and Future Challenges of Innovative Oncology Drug Development
CDDF Cancer Drug Development Forum CDDF 10 TH ALPINE CONFERENCE Current and Future Challenges of Innovative Oncology Drug Development Innsbruck, Austria 26-28 February 2018 PROGRAMME PROGRAMME Day 1 Monday
6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY June 2016 Berlin, Germany. Chairs: A. Eggert, DE B. Morland, UK R.
MASTERCLASS 6 TH ESO-SIOP EUROPE MASTERCLASS IN PAEDIATRIC ONCOLOGY Held with the support of 11-16 June 2016 Berlin, Germany Chairs: A. Eggert, DE B. Morland, UK R. Riccardi, IT INTRODUCTION ESO and SIOP-Europe
Access to innovative oncology medicines in Europe January 2014 Bonn, Germany BDA WORKSHOP BIOTHERAPY DEVELOPMENT ASSOCIATION
BDA WORKSHOP Access to innovative oncology medicines in Europe 16-17 January 2014 Bonn, Germany BIOTHERAPY DEVELOPMENT ASSOCIATION Content Meeting Objectives 2 Organising Committee 2 Who should attend?
Consultation in relation to the Paediatric Report
Consultation in relation to the Paediatric Report Ref. PCPM/16 Paediatric Report Response from The Institute of Cancer Research, London and The Royal Marsden NHS Foundation Trust Consultation item No 1:
The EU paediatric medicine regulation: from a paediatric oncology network
The EU paediatric medicine regulation: candid is it working? A λview from a paediatric oncology network Bruce Morland Birmingham Children s Hospital & Innovative Therapies for Children with Cancer The
Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients
22 August 2018 EMA/242738/2018 Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients 5-6 September 2018 30 Churchill
SIOP. 7 TH ESO-SIOP EUROPE MASTERCLASS IN PaEDiatRic OncOlOGy June 2018 nauen Ot Groß Behnitz (Berlin area), Germany.
SIOP SIOP Europe the European Society for Paediatric Oncology 7 TH ESO-SIOP EUROPE MASTERCLASS IN PaEDiatRic OncOlOGy 16-21 June 2018 nauen Ot Groß Behnitz (Berlin area), Germany Chairs: S. Bielack, DE
Drug Development in Paediatric Oncology
Drug Development in Paediatric Oncology Koen Norga, MD, PhD Paediatric Oncology, UZA External clinical expert, FAMHP PDCO, vice-chair and member (BE), EMA CHMP, co-opted member (pharmacology), EMA Drug
ANSWER FROM PARENTS ORGANIZATIONS. This is a collective answer to the Public Consultation co-signed by :
GENERAL REPORT ON EXPERIENCE ACQUIRED AS A RESULT OF THE APPLICATION OF THE PAEDIATRIC REGULATION (ARTICLE 50(2) OF REGULATION (EC) NO 1901/2006) EXPERIENCE ACQUIRED AND LESSONS LEARNT SUBMITTED FOR PUBLIC
ECPC ANNUAL CONGRESS ECPC GENERAL ASSEMBLY
ECPC ANNUAL CONGRESS FRIDAY 8 SATURDAY 9 JUNE 2018 & ECPC GENERAL ASSEMBLY SUNDAY 10 JUNE 2018 VENUE: RENAISSANCE BRUSSELS HOTEL, RUE DU PARNASSE 19, 1050 BRUXELLES EVENT ORGANISED UNDER THE HIGH PATRONAGE
EuropaColon Expands into Digestive Cancers Europe. Our objective is to save an additional 250,000 Europeans every year
PRESS RELEASE Monday 22nd October 2018 EuropaColon Expands into Digestive Cancers Europe Our objective is to save an additional 250,000 Europeans every year Munich, 22 October 2018 EuropaColon, the European
Update on public hearing
Update on public hearing PCWP/HCPWP joint meeting Presented by Juan Garcia Burgos on 0 September 017 Head of Public Engagement Department An agency of the European Union A public hearing provides An opportunity
Striving for Professionalism in IITs
EFGCP Workshop on Striving for Professionalism in IITs 26 & 27 February 2014 Courtyard Hotel, Brussels, Belgium Organised by European Forum for Good Clinical Practice In Collaboration with www.efgcp.eu
Specific Challenges for Orphan Drugs with Paediatric Development
Specific Challenges for Orphan Drugs with Paediatric Development Tsveta Schyns-Liharska, PhD ENRAH Member of the PDCO, EMA Representing Patients and EURORDIS Disclaimer Some of the slides in this presentation
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016
Pfizer Support to European and International Patient Organisations based in Belgium & Luxembourg in 2016 Please note that all information in this document is also disclosed in the overall report on Pfizer
Ethical Challenges in Clinical Research at Both Ends of Life
Preliminary Programme, 24 February 2010 v5 EFGCP-EUCROF Joint Workshop on Ethical Challenges in Clinical Research at Both Ends of Life Common Lessons to be learnt from Paediatric & Geriatric Clinical Development
Successful practice changing development plans: Rituximab in Burkitt lymphoma
Successful practice changing development plans: Rituximab in Burkitt lymphoma Véronique Minard-Colin, MD, PhD Pediatric and Adolescent Oncology Gustave Roussy, Villejuif, France No disclosure CD20 immunotherapy
Pediatric Drug Development: Successes and Challenges
Pediatric Drug Development: Successes and Challenges Lynne Yao, M.D. Director, Division of Pediatric and Maternal Health Office of New Drugs Center for Drug Evaluation and Research U.S. FDA September 23,
Class waiver list review
Class waiver list review Background, approach and outcome Consequences for regulatory submissions EMA Industry stakeholder platform on Paediatric medicines Presented by Ralf Herold on 11 May 2015 Paediatric
PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE
PROVISIONAL SCIENTIFIC PROGRAMME AND TIMETABLE Thursday 17 th October, 2013 09.00- : Executive meetings (only for the Executive and the International Advisory Boards of EURIPA and the Executive of EGPRN),
This meeting has been made possible by an independent grant from Roche.
This meeting has been made possible by an independent grant from Roche. This event has been created in collaboration between the University of Milan and ecancer. MILAN SUMMIT ON PRECISION MEDICINE AGENDA
The Paediatric Committee (PDCO)
www.eurordis.org The Paediatric Committee (PDCO) Fernando de Andres-Trelles (UCM, PDCO, AEMPS) Barcelona, June 2013 1 Some of the slides based on EMA sources, gratefully acknowledged* but opinions are
EURORDIS SUMMER SCHOOL EXPRESS YOURSELF!
EXPERT PATIENTS AND RESEARCHERS EURORDIS SUMMER SCHOOL EXPRESS YOURSELF! CASTELLDEFELS, BARCELONA, SPAIN JUNE 11-15, 2018 A capacity building programme for patient representatives & researchers on medicines
REGULATION AND HTA OF MEDICAL DEVICES IN EU: WHAT CAN WE LEARN?
REGULATION AND HTA OF MEDICAL DEVICES IN EU: WHAT CAN WE LEARN? Rosanna Tarricone, PhD Associate Dean, Government Health and Non Profit Division Issue Panel Opportunities and challenges in international
EMA/FDA/Health Canada workshop on paediatric pulmonary arterial hypertension (PAH)
12 June 2017 EMA/848554/2016 Rev.1 Human Medicines Research and Development Support Division EMA/FDA/Health Canada workshop on paediatric pulmonary arterial hypertension (PAH) 12-13 June 2017, meeting
Table Of Content. Outputs... 9
Table Of Content European Expert Paediatric Oncology Reference Network for Diagnostics and Treatment... 2 Summary... 3 Coordinator, Leader contact and partners... 5 Klinikum Dortmund ggmbh... 5 Uniwersytet
European Patients Academy on Therapeutic Innovation
European Patients Academy on Therapeutic Innovation http://www.patientsacademy.eu info@patientsacademy.eu The project is receiving support from the Innovative Medicines Initiative Joint Undertaking under
European Paediatric Network Legal Basis
Enpr-EMA Joint DIA/EFGCP/EMA Paediatric Forum 26 September 2011 Paolo Rossi Chairman Dept. of Pediatrics Tor Vergata University-Children s Hospital Bambino Gesù, Rome EnprEMA-PDCO Representative An agency
ASCONA 07/11/08 PAEDIATRIC ONCOLOGY. 2 nd ESO-SIOPE MASTERCLASS IN November 2008 Ascona, Switzerland
MASTERCLASS ASCONA 07/11/08 2 nd ESO-SIOPE MASTERCLASS IN PAEDIATRIC ONCOLOGY 7-13 November 2008 Ascona, Switzerland Chair: R. Riccardi, IT - M.C.G. Stevens, UK - A. Eggert, DE Educational Advisor: W.
Table Of Content. Page 1/8
Table Of Content 22nd Conference: Changing perceptions, practice and policy... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04-00 - Programme and book of abstracts (EN)...
Media Release. Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia
Media Release Roche announces EU approval of Venclyxto plus MabThera for people with previously treated chronic lymphocytic leukaemia Approval is based on randomised phase III MURANO study showing that
The EU PIP - a step in Pediatric Drug Development. Thomas Severin Bonn,
The EU PIP - a step in Pediatric Drug Development Thomas Severin Bonn, 13.01.2009 Agenda Implications for Industry Company Preparation Time of PIP Submission Content of the PIP The PIP Process and first
Request for Letters of Intent. International Development of H5N1 Influenza Vaccines
Request for Letters of Intent International Development of H5N1 Influenza Vaccines The World Health Organization (WHO) intends to provide funding to developing (1) country vaccine manufacturers to develop
20 th MCCR WORKSHOP METHODS IN CLINICAL CANCER RESEARCH. Zeist, Netherlands Society Grant Prospectus 2018 JUNE. ecco-org.
20 th MCCR WORKSHOP METHODS IN CLINICAL CANCER RESEARCH Zeist, Netherlands Society Grant Prospectus 2018 16-22 JUNE 2018 ecco-org.eu/workshop TABLE OF CONTENT 1. INTRODUCTION 3 2. EDUCATIONAL FORMAT 5
Regulatory incentives: Experience from European Medicines Agency
Regulatory incentives: Experience from European Medicines Agency European Medicines Agency Presented by: Nathalie Seigneuret An agency of the European Union EU Paediatric Regulation: Objectives Improve
PHOTO. VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe
www.eurordis.org VHPB/ELPA MEETING Prevention and Control of Viral Hepatitis The role and impact of patients and advocacy groups in and outside Europe Lucca ( Italy ) March 13-14, 2008 PHOTO www.eurordis.org
EU REGULATORY AND LEGAL CONSTRAINTS TO CLINICAL TRIALS ON RARE CANCERS
EU REGULATORY AND LEGAL CONSTRAINTS TO CLINICAL TRIALS ON RARE CANCERS Rare Cancers Conference Anastassia Negrouk Head of International Regulatory and Intergroup, EORTC 1 CONTENT 1. Introduction 2. Landscape
VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY. 8-9 April 2011 Viareggio, Italy. Chair: M. Aapro, CH
ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA VIAREGGIO 08/04/11 GENE PROFILING IN CLINICAL ONCOLOGY 8-9 April 2011 Viareggio, Italy Chair: M. Aapro, CH Dear Colleagues, The European School of Oncology is
Table Of Content. European Organisation for Rare Diseases... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs...
Table Of Content European Organisation for Rare Diseases... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04 - Electronic Newsletter (EN)... 7 D01 - Activity Report EURORDIS
Media Release. Basel, 12 December 2017
Media Release Basel, 12 December 2017 Roche announces phase III data showing Venclexta/Venclyxto plus MabThera/Rituxan reduced the risk of disease progression or death by 83% compared to a standard of
A Summary of Childhood Cancer Statistics in Australia,
What is the Australian Paediatric Cancer Registry (APCR)? The APCR is one of only a few national registries of childhood cancer in the world. It covers all Australian children aged 0-14 years old at diagnosis.
OECI accreditation: is yours a top-class cancer centre?
OECI accreditation: is yours a top-class cancer centre? Whether you work at a cancer unit, a cancer centre or a comprehensive cancer centre, applying for OECI accreditation is a good way to find out how
PRELIMINARY PROGRAMME H&N Preceptorship: focus on comprehensive management Nice, France
PRELIMINARY PROGRAMME H&N Preceptorship: focus on comprehensive management Live educational course dates The live educational course H&N Preceptorship: Focus on comprehensive management" will be held on
Liver Forum Cirrhosis Working Group Arun J. Sanyal
Liver Forum Cirrhosis Working Group Arun J. Sanyal Z Reno Vlahcevic Professor of Medicine VCU School of Medicine Richmond, VA 2 Liver Forum 8 DRUG DEVELOPMENT PATHWAYS Regular approval pathway: based on
Overall survival: 1 st line therapy
1 3 Overall survival: 1 st line therapy 2-year OS phase III studies mm Prices per month of oncology medicin Bloomberg Business weekly 26 Feb 2015 Presented By Veena Shankaran at 2016 ASCO Annual Meeting
Global Pediatric Development: We Are Making Progress. PMDA Perspective. Junko Sato, PhD PMDA
Global Pediatric Development: We Are Making Progress PMDA Perspective Junko Sato, PhD PMDA Disclaimer The views and opinions expressed in the following PowerPoint slides are those of the individual presenter
The challenge of vaccine hesitancy in the European Union
The challenge of vaccine hesitancy in the European Union Michael Sulzner AIM SEMINAR Vaccine hesitancy, a global trend which threatens public health 11 December 2017, Brussels Outline - Competence - Political
Improving new drug development for paediatric cancer: the EMA and PDCO vision
Dr. Dirk Mentzer, MD, PhD Consultant General Paediatrics Head of Pharmacovigilance unit Chair of PDCO at EMA Paul-Ehrlich-Institut Federal Institute for Vaccines and Biomedicines, Germany Disclaimer The
SCIENTIFIC TIMETABLE SIOP 2015
SCIENTIFIC TIMETABLE SIOP 2015 September, 2015 WEDNESDAY, 7 TH OCTOBER 2015 / DAY 2 1.43 09:30 SIOP Committee 12:00 SIOP Essential Drugs Working 13:00 SIOP Work (Open) 14:00 Nurse Researchers 16:00 17:00
ECOO European Diploma in Optometry and Optics ECOO European Diploma in Optics A Status Report
ECOO European Diploma in Optometry and Optics ECOO European Diploma in Optics A Status Report Peter Gumpelmayer, BOptom, EurOptom ECOO President-elect ECOO The European Council of Optometry and Optics
On 24 May 2005 the Council (GAERC), in its formation of Development Ministers, adopted the conclusions in Annex I.
COUNCIL OF THE EUROPEAN UNION Brussels, 24 May 2005 9278/05 DEVGEN 92 RELEX 257 SAN 74 ONU 61 ACP 73 NOTE from : General Secretariat dated 24 May 2005 No. prev. doc. : 9085/05 DEVGEN 88 RELEX 238 SAN 62
Multi-sectoral aspects of pandemic preparedness and response
Multi-sectoral aspects of pandemic preparedness and response Best practices, challenges and lessons learned in the EU International Ministerial Conference on Avian & Pandemic Influenza Sharm el Sheikh,
A multi-stakeholder partnership initiative. 10 February 2012
A multi-stakeholder partnership initiative 10 February 2012 1 History 39 recommendations on stakeholder actions and public policies:» 8 addressing regulatory barriers in rare cancer care» 11 addressing
Cancer prevention and control in the context of an integrated approach
SEVENTIETH WORLD HEALTH ASSEMBLY A70/A/CONF./9 Agenda item 15.6 25 May 2017 Cancer prevention and control in the context of an integrated approach Draft resolution proposed by Brazil, Canada, Colombia,
WHO Research Agenda for RF fields
WHO Research Agenda for RF fields Dr E. van Deventer 1 Outline Introduction The WHO RF Research Agenda Motivation Background Content Discussion 2 3 Established in 1996 Coordinated by WHO HQ (SDE/PHE/RAD)
Preliminary programme ESLCCC September 2016
Preliminary programme ESLCCC 2016 22-23 September 2016 1 st day - Thursday 22 September 2016 8.45 17.00 Registration starts at 7.30 in the morning Welcome and Introduction By the ESLCCC 16 Committee Female
ESMO 2020 VISION. esmo.org
ESMO 2020 VISION esmo.org CARING FOR PEOPLE WITH CANCER Cancer patients and their needs are at the centre of all that we do: our profession is driven by our determination, individually and collectively,
Movember Netherlands. Policy Plan
Movember Netherlands Policy Plan 2013 1 Organsiation vision, values & goals 1.1 VISION Movember s vision is to have an everlasting impact on the face of men s health 1.2 VALUES The organsiation s values
Economic and Social Council
United Nations Economic and Social Council Distr.: General 13 September 2013 ECE/WG.1/2013/4 Original: English Economic Commission for Europe Working Group on Ageing Sixth meeting Geneva, 25-26 November
Standardised Lab Manual for bioanalytical support in clinical studies : Introducing the harmonised Lab Manual. Introduction to the Workshop
Standardised Lab Manual for bioanalytical support in clinical studies : Introducing the harmonised Lab Manual Introduction to the Workshop Philip Timmerman (for EBF) 05 February 2014 NH Sablon Hotel, Brussels
Media Release. Basel, 7 November 2013
Media Release Basel, November 2013 Roche s Gazyva helped people with one of the most common forms of blood cancer live significantly longer without their disease worsening compared to MabThera/Rituxan
CFS MYPoW Chair Proposal on the HLPE work in 2018
Open Ended Working Group (OEWG) Multi-Year Programme of Work (MYPoW) Document No: CFS OEWG- MYPoW/2016/06/20/01 CFS OEWG-MYPoW Meeting # 02 Date: 20 June 2016 Time: 9.30-12.30 Location: Lebanon Room, FAO
REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES
Information Brief: REPRODUCTIVE, MATERNAL, NEWBORN AND CHILD HEALTH (RMNCH) GLOBAL AND REGIONAL INITIATIVES Family Care International (FCI) developed this information brief as part of the Mobilising Advocates
9/20/2011. Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience
Impact of EU Paediatric Regulation on drug development and Marketing authorisations Industry experience Judith Creba Head EU Liaison and Policy, DRA Novartis Pharma AG, Switzerland Disclaimer The views
EC research and innovation strategy and actions
EC research and innovation strategy and actions for preparedness and response to outbreaks IMI Stakeholder Forum 28-29 September 2016 Line Matthiessen Head of Unit E.3 Health Directorate DG Research &
6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia
6 Opportunities for Improving Pathways to Market: A Global Perspective on Dementia Raj Long Senior Regulatory Officer Bill & Melinda Gates Foundation Director Dementia Integrated Development UK HMG World
(+1) Matti Ojanen (+44) Investor Contact: Jennifer M. Davis (+1)
For immediate release: October 24, 2012 Media Contact: Victoria Davis (+1) 347-558-3455 Matti Ojanen (+44) 7557-202-394 Investor Contact: Jennifer M. Davis (+1) 212-733-0717 Pfizer s XALKORI Receives Conditional
ESTS SCHOOL FIRST ESTS-ERS COLLABORATIVE COURSE ON THORACIC ONCOLOGY A MULTIDISCIPLINARY UPDATE ON POTENTIALLY OPERABLE LUNG CANCER
SCHOOL FIRST -ERS COLLABORATIVE COURSE ON ONCOLOGY A MULTIDISCIPLINARY UPDATE ON POTENTIALLY OPERABLE LUNG CANCER 11-13 February 2019 Hamburg, Germany An application will be made for accreditation to European
oncology For 9 th eso-esmo course on July 2012 ioannina, Greece
ESO ADVANCED COURSES, SEMINARS AND SYMPOSIA ioannina 21/07/12 9 th eso-esmo course on oncology For medical students 21-27 July 2012 ioannina, Greece chair: N. Pavlidis, GR core faculty: R.A. Audisio, UK
Table Of Content. EURORDIS_FY Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7
Table Of Content EURORDIS_FY2010... 2 Summary... 3 Coordinator, Leader contact and partners... 6 Outputs... 7 D04 - Electronic Newsletter and V.3 of EURORDIS website (EN)... 7 D01 - Activity Report OPERA
Preliminary Programme
2019 Bone Curriculum Symposium Friday 15 March 2019 Pre-Symposium Course on Rare Bone Diseases Friday 15 and Saturday 16 March 2019 Organised by the KBVR/SRBR Osteoporosis and Fracture Prevention Group
TARCEVA NEARLY DOUBLED THE TIME PEOPLE WITH A GENETICALLY DISTINCT TYPE OF LUNG CANCER LIVED WITHOUT THEIR DISEASE GETTING WORSE
NEWS RELEASE Genentech Contacts: Media Contact: Charlotte Arnold (650) 467-6800 Advocacy Contact: Jen Mills (650) 467-6722 Investor Contacts: Thomas Kudsk Larsen (650) 467-2016 Karl Mahler 011 41 61 687
Joint Programming in Neurodegenerative Disease Research (JPND)
Joint Programming in Neurodegenerative Disease Research (JPND) Building Alliances and Collaborations Prof. Philippe Amouyel, MD, PhD JPND Chair France Disclosure CEO of Fondation Plan Alzheimer Conference
Survey Responses to the EUROPEAN COCOA FORUM 2016
Survey Responses to the EUROPEAN COCOA FORUM The survey was sent to all delegates, speakers and moderators who took part in the European Cocoa Forum in Dubrovnik, and aimed at gathering feedback on the
PRELIMINARY PROGRAMME
0 PRELIMINARY PROGRAMME OVERVIEW The aim of the symposium is to provide quality education, based on practical clinical experience, on all aspects of the nurse s role related to the management of thyroid
Type 1 Diabetes Australian Research Impact Analysis
Type 1 Diabetes Australian Research Impact Analysis Executive Overview Summary Type 1 diabetes research in Australia Australia is making a significant contribution to the quantity and quality of the global
FEBS 2019 Advanced Lecture Course. Biological Surfaces and Interfaces: The Mechanistic View.
FEBS 2019 Advanced Lecture Course Biological Surfaces and Interfaces: The Mechanistic View. June 30 July 5, 2019 Hotel Eden Roc Sant Feliu de Guixols, Spain Preliminary Program Chair Marta Bally Umeå University
What is new. Sandra Caldeira, Joint Research Centre
What is new Joint Meeting of the High Level Group on Nutrition and Physical Activity and the EU Platform for Action on Diet, Physical Activity and Health Brussels, 10 June 2014 Sandra Caldeira, Joint Research
Peer counselling A new element in the ET2020 toolbox
shutterstock Peer counselling A new element in the ET2020 toolbox Information Note. Main characteristics of the peer counselling tool Peer learning in the context of the education cooperation at EU level
39th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland. 6-8 December 2016
8 December 2016 39th Meeting of the UNAIDS Programme Coordinating Board Geneva, Switzerland 6-8 December 2016 Decisions The UNAIDS Programme Coordinating Board, Recalling that all aspects of UNAIDS work
POSITION DESCRIPTION. Employment Status: Maternity Leave Contract 5 months (Jan-May 2018) PURPOSE OF POSITION DESCRIPTION
POSITION DESCRIPTION Position Title: Location: Research Coordinator Clinical Trials National Secretariat, Brisbane-based Employment Status: Maternity Leave Contract 5 months (Jan-May 2018) Reporting Relationships:
Subject: The 9 th Meeting of the Joint CEOS/CGMS Working Group on Climate. Dear Colleagues,
Our ref.: EUM/OPS/LET/18/975872 Subject: The 9 th Meeting of the Joint CEOS/CGMS Working Group on Climate Dear Colleagues, I am pleased to invite you to the 9 th Meeting of the Joint CEOS/CGMS Working
Commissioner Borg addresses the European Parliament's Interest Group on Complementary and Alternative Medicine
Tonio Borg Member of the European Commission, responsible for Health and Consumer Policy Commissioner Borg addresses the European Parliament's Interest Group on Complementary and Alternative Medicine Tonio
The European Food Safety Summit
The European Food Safety Summit The European Food Safety Summit, which was organised on 22nd November 2007 by EFSA jointly with the Portuguese Presidency and the European Commission, was a highlight of
Fondazione IRCCS, Istituto Nazionale dei Tumori. 2-4 March Milan, Italy
PRACTICE TEACHING COURSE PRELIMINARY PROGRAMME Practice teaching course in head and neck cancer, 2-4 March 2016 - Overview Head and neck cancer treatment requires multidisciplinary cooperation between
Final Workshop. Patients Partnering in Clinical Trials. 7 & 8 December 2010 Management Centre Europe Brussels, Belgium
, Final Workshop Patients Partnering in Clinical Trials 7 & 8 December 2010 Management Centre Europe Brussels, Belgium Programme Committee Melissa Hillier Genetic Alliance UK, United Alastair Kent Genetic
Accelerating the Pace of Chemical Risk Assessments
Accelerating the Pace of Chemical Risk Assessments An International Workshop Hosted by the US EPA September 14-15, 2016 in Washington DC Robert Kavlock, US EPA European Commission Scientific Conference
Discovery and validation of novel. Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies
Discovery and validation of novel Webinar IMI2 - Call 9 Joint influenza vaccine effectiveness studies Dr. Angela Wittelsberger, IMI IMI webinar 29.04.2016 Today s webinar Will cover all aspects of the
CALL FOR PROPOSAL. The conference secretariat at the International AIDS Society (IAS) will serve as a mailbox for applications.
CALL FOR PROPOSAL Due to the timing of the 20th International AIDS Conference (AIDS 2014), the conference organizers recognize that there is a need for a key hub to be held after Ramadan in the Asia Pacific